MCID: PRS040
MIFTS: 90

Prostate Cancer

Categories: Genetic diseases, Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Prostate Cancer

MalaCards integrated aliases for Prostate Cancer:

Name: Prostate Cancer 57 38 12 25 75 37 13 55 43 3 15 63
Prostate Cancer, Familial 57 12 76 53 73
Prostate Carcinoma 12 25 55 15 73
Prostate Neoplasm 12 25 29 6
Familial Prostate Cancer 53 59 29
Prostate Cancer, Susceptibility to 57 6
Malignant Tumor of Prostate 29 6
Hereditary Prostate Cancer 12 53
Prostate Cancer, Somatic 57 6
Prostatic Neoplasms 44 73
Prostatic Neoplasm 12 25
Prostatic Cancer 12 25
Prostate Cancer, Familial, Susceptibility to 57
Prostate Cancer, Susceptibility to, Somatic 57
Prostate Cancer, Susceptibility to, 4 57
Prostate Cancer, Susceptibility to, 3 57
Malignant Neoplasm of the Prostate 25
Prostate Cancer, Progression of 57
Malignant Tumor of the Prostate 12
Prostate Cancer, Hereditary, 5 57
Malignant Neoplasm of Prostate 73
Ngp - New Growth of Prostate 12
Prostate Cancer, Hereditary 53
Prostate Cancer Somatic 57
Cancer of the Prostate 25
Tumor of the Prostate 12
Carcinoma of Prostate 12
Prostatic Carcinoma 25
Cancer of Prostate 12
Prostate Cancer 4 57
Prostate Cancer 3 57
Cancer, Prostate 40
Prca 75
Pc 75

Characteristics:

Orphanet epidemiological data:

59
familial prostate cancer
Prevalence: 1-9/100000 (United States); Age of onset: Adult;

OMIM:

57
Inheritance:
autosomal dominant form


HPO:

32
prostate cancer:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 59  
Rare urogenital diseases


External Ids:

OMIM 57 176807
Disease Ontology 12 DOID:10283 DOID:10286
ICD10 33 C61
ICD9CM 35 185
MeSH 44 D011471
Orphanet 59 ORPHA1331
MESH via Orphanet 45 C537243
UMLS via Orphanet 74 C2931456
ICD10 via Orphanet 34 C61
MedGen 42 C0376358
KEGG 37 H00024
SNOMED-CT via HPO 69 263681008

Summaries for Prostate Cancer

MedlinePlus : 43 The prostate is the gland below a man's bladder that produces fluid for semen. Prostate cancer is common among older men. It is rare in men younger than 40. Risk factors for developing prostate cancer include being over 65 years of age, family history, and being African-American. Symptoms of prostate cancer may include Problems passing urine, such as pain, difficulty starting or stopping the stream, or dribbling Low back pain Pain with ejaculation To diagnose prostate cancer, you doctor may do a digital rectal exam to feel the prostate for lumps or anything unusual. You may also get a blood test for prostate-specific antigen (PSA). These tests are also used in prostate cancer screening, which looks for cancer before you have symptoms. If your results are abnormal, you may need more tests, such as an ultrasound, MRI, or biopsy. Treatment often depends on the stage of the cancer. How fast the cancer grows and how different it is from surrounding tissue helps determine the stage. Men with prostate cancer have many treatment options. The treatment that's best for one man may not be best for another. The options include watchful waiting, surgery, radiation therapy, hormone therapy, and chemotherapy. You may have a combination of treatments. NIH: National Cancer Institute

MalaCards based summary : Prostate Cancer, also known as prostate cancer, familial, is related to breast cancer and ovarian cancer, and has symptoms including angina pectoris, tremor and equilibration disorder. An important gene associated with Prostate Cancer is PTEN (Phosphatase And Tensin Homolog), and among its related pathways/superpathways are Prostate cancer and Transcriptional misregulation in cancer. The drugs Degarelix and Eligard have been mentioned in the context of this disorder. Affiliated tissues include the prostate, prostate and bone, and related phenotypes are prostate cancer and cellular

UniProtKB/Swiss-Prot : 75 Prostate cancer: A malignancy originating in tissues of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.

NIH Rare Diseases : 53 Familialprostate cancer is a cluster of prostate cancer within a family. Most cases of prostate cancer occur sporadically in people with no family history of the condition. However, approximately 5% to 10% of prostate cancer cases are believed to be primarily caused by a genetic predisposition to the condition. In many families, the underlying genetic cause is unknown; however, some of these cases are caused by changes (mutations) in the BRCA1, BRCA2, HOXB13, or several other genes. Other cases are likely due to a combination of gene(s) and other shared factors such as environment and lifestyle.High-risk cancer screening at an earlier age is typically recommended in men who have an increased risk for prostate cancer based on personal and/or family histories.

CDC : 3 Prostate cancer is the most common non-skin cancer among American men. Prostate cancers usually grow slowly. Most men with prostate cancer are older than 65 years and do not die from the disease. Finding and treating prostate cancer before symptoms occur may not improve your health or help you live longer.

Genetics Home Reference : 25 Prostate cancer is a common disease that affects men, usually in middle age or later. In this disorder, certain cells in the prostate become abnormal and multiply without control or order to form a tumor. The prostate is a gland that surrounds the male urethra and helps produce semen, the fluid that carries sperm.

Disease Ontology : 12 A male reproductive organ cancer that is located in the prostate.

Novus Biologicals : 56 Prostate cancer is the most common non-skin cancer and second most deadly cancer for men in the United States. Prostate cancer occurs when cells within the prostate grow uncontrollably and create small tumors. If untreated, cells from these tumors can spread via metastasis. Metastasis transports prostate cancer cells through the lymphatic system and bloodstream to other parts of the body where they can grow into secondary tumors. PSA, a protein produced by the prostate, is released into the bloodstream in small amounts under normal conditions. However, PSA is released in increasing amounts when the prostate is malfunctioning, as is the case with prostate cancer.

PubMed Health : 63 About prostate cancer: Prostate cancer develops when cells in the prostate start multiplying uncontrollably. This can happen if the genetic information (DNA) in the cells has changed (mutated). The body’s immune system usually keeps these cells in check. Cancer develops if too many mutated cells multiply and a tumor grows.The diagnosis “prostate cancer” usually comes as a shock to men and those close to them. The good news is that prostate cancer is one of the types of cancer with the best chances of recovery. This is because it often grows very slowly so it is generally possible to treat it effectively.

Wikipedia : 76 Prostate cancer is the development of cancer in the prostate, a gland in the male reproductive system.... more...

Description from OMIM: 176807

Related Diseases for Prostate Cancer

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 1 Prostate Cancer, Hereditary, 8
Prostate Cancer, Hereditary, 3 Prostate Cancer, Hereditary, 4
Prostate Cancer, Hereditary, 5 Prostate Cancer, Hereditary, 6
Prostate Cancer, Hereditary, 7 Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 10 Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 13 Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 14 Prostate Cancer, Hereditary, 15
Prostate Cancer, Hereditary, 2 Prostate Carcinoma in Situ

Diseases related to Prostate Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 407)
# Related Disease Score Top Affiliating Genes
1 breast cancer 34.3 AR BRCA2 CDH1 CHEK2 MIR145 MIR146A
2 ovarian cancer 33.2 BRCA2 CDH1 CHEK2 MIR146A MIR21 MIR221
3 bladder cancer 33.1 CDH1 MIR145 MIR205 MIR21 MIR221 MIR222
4 suppression of tumorigenicity 12 33.0 AR KLF6 PTEN TP53
5 lung cancer 33.0 CDH1 CHEK2 MIR145 MIR146A MIR205 MIR21
6 gastric cancer 33.0 CDH1 KLF6 MIR145 MIR21 MIR221 MIR222
7 melanoma 32.9 MIR205 MIR221 MIR222 MIR23B PTEN TP53
8 glioblastoma 32.7 BRCA2 MIR21 MIR221 MIR222 MIR23B PTEN
9 hepatocellular carcinoma 32.7 CDH1 MIR145 MIR146A MIR205 MIR21 MIR221
10 pancreatic cancer 32.4 BRCA2 CDH1 MIR146A MIR205 MIR21 MIR221
11 esophageal cancer 32.3 CDH1 CHEK2 MIR205 MIR21 PTEN TP53
12 squamous cell carcinoma, head and neck 32.3 CDH1 MIR205 MIR21 MIR221 PTEN TP53
13 glioma 32.3 BRCA2 MIR21 MIR221 MIR222 PTEN TP53
14 li-fraumeni syndrome 32.2 BRCA2 CHEK2 PTEN TP53
15 testicular germ cell tumor 32.2 AR MIR145 PTEN TP53
16 leukemia, chronic lymphocytic 32.0 MIR145 MIR146A MIR21 MIR221 MIR23B TP53
17 glioblastoma multiforme 31.9 MIR21 MIR221 PTEN TP53
18 oral cancer 31.8 CDH1 MIR21 TP53
19 dermatomyositis 31.7 MIR21 MIR221 MIR222
20 transitional cell carcinoma 31.6 CDH1 PTEN TP53
21 li-fraumeni syndrome 2 31.6 CHEK2 TP53
22 cervical cancer 31.2 MIR21 MIR23B PTEN TP53
23 prostate cancer, hereditary, 1 12.5
24 prostate cancer, hereditary, 2 12.3
25 prostate cancer, hereditary, 13 12.3
26 prostate cancer, hereditary, 12 12.3
27 prostate cancer, hereditary, 11 12.3
28 prostate cancer, hereditary, 4 12.2
29 adenosquamous prostate carcinoma 12.2
30 prostate cancer, hereditary, 7 12.2
31 male reproductive organ cancer 12.1 AR CDH1 PTEN RNASEL TP53
32 prostate cancer, hereditary, x-linked 1 12.0
33 prostate cancer/brain cancer susceptibility 12.0
34 prostate cancer, hereditary, 8 12.0
35 prostate cancer, hereditary, 9 12.0
36 sporadic breast cancer 12.0 BRCA2 CHEK2 PTEN TP53
37 prostate cancer, hereditary, x-linked 2 12.0
38 prostate cancer, hereditary, 3 12.0
39 prostate cancer, hereditary, 5 12.0
40 prostate cancer, hereditary, 6 12.0
41 prostate cancer, hereditary, 10 12.0
42 prostate cancer, hereditary, 14 12.0
43 prostate cancer, hereditary, 15 12.0
44 hereditary breast ovarian cancer syndrome 12.0 BRCA2 CHEK2 PTEN TP53
45 ductal carcinoma in situ 12.0 AR BRCA2 CDH1 TP53
46 female reproductive organ cancer 12.0 BRCA2 CDH1 PTEN TP53
47 prostate carcinoma in situ 12.0
48 prostate cancer, progression and metastasis of 11.9
49 adenoid cystic carcinoma 11.9 CDH1 CHEK2 PTEN TP53
50 wilms tumor 1 11.9 AR BRCA2 CHEK2 TP53

Comorbidity relations with Prostate Cancer via Phenotypic Disease Network (PDN): (show all 35)


Acute Kidney Failure Anthracosis
Asbestosis Azoospermia
Balanoposthitis Bladder Cancer
Bladder Neck Obstruction Chronic Kidney Failure
Cystitis Cystica Deficiency Anemia
Disseminated Intravascular Coagulation Epididymo-Orchitis
Gout Hydronephrosis
Kidney Disease Lipoma of Spermatic Cord
Lymphadenitis Nephrolithiasis, X-Linked Recessive, with Renal Failure
Oligospermia Paralytic Ileus
Paraplegia Prostate Calculus
Prostate Carcinoma in Situ Prostate Disease
Prostatic Hypertrophy Prostatitis
Radiation Cystitis Spermatocele
Spinal Cord Disease Ureterolithiasis
Urethral Benign Neoplasm Urethral Calculus
Urethral Stricture Urethritis
Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Prostate Cancer:



Diseases related to Prostate Cancer

Symptoms & Phenotypes for Prostate Cancer

Symptoms via clinical synopsis from OMIM:

57
Oncology:
early onset prostate cancer


Clinical features from OMIM:

176807

Human phenotypes related to Prostate Cancer:

32
# Description HPO Frequency HPO Source Accession
1 prostate cancer 32 HP:0012125

UMLS symptoms related to Prostate Cancer:


angina pectoris, tremor, equilibration disorder

MGI Mouse Phenotypes related to Prostate Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10 CDH1 CHEK2 KLF6 MAD1L1 MXI1 POLK
2 endocrine/exocrine gland MP:0005379 9.9 CDH1 ZFHX3 CHEK2 KLF6 MAD1L1 MXI1
3 neoplasm MP:0002006 9.61 CHEK2 MAD1L1 MXI1 PTEN AR BRCA2
4 reproductive system MP:0005389 9.28 CDH1 ZFHX3 KLF6 MAD1L1 MXI1 PTEN

Drugs & Therapeutics for Prostate Cancer

PubMedHealth treatment related to Prostate Cancer: 63

The possible treatment options for prostate cancer will depend on various factors. These include:how much the cells have changed (how aggressive the tumor is)how much the tumor has grown or spread (the stage of prostate cancer)the man’s PSA levelsindividual factors such as the man’s age, how healthy he is otherwise, and how important the pros and cons are to him.Men who have high-risk prostate cancer will usually have their prostate surgically removed or treatment with radiotherapy. Radiotherapy can be done in two ways: from outside of the body (external radiotherapy) or from inside the body (internal radiotherapy, or brachytherapy).The most common side effects of radiotherapy or removing the prostate gland are accidental leakage of urine (urinary incontinence) and erection problems (impotence). External radiotherapy is especially likely to cause diarrhea, and in some cases inflammations in the bowel which may result in blood in the stool and cramps.If the tumor is small, only inside the prostate, and not aggressive (low-risk prostate cancer), the following treatments are also possible:Active surveillance: Here the prostate cancer is simply monitored, and not treated, at first. This strategy is based on the fact that low-risk prostate cancer usually grows very slowly or doesn't grow at all. It is often found that the cancer has still not advanced even years after it was diagnosed. Instead of having treatment, the prostate is checked regularly. Treatment attempting to get rid of the cancer (curative treatment) is only started if the tumor starts growing. The advantage of this approach is that the side effects of surgery or radiotherapy can be avoided as long as the cancer does not grow. One possible disadvantage: If the cancer does progress, that is sometimes discovered too late. It may have already spread to other parts of the body by then (metastasis). Knowing that you have cancer in your body can be distressing too.Watchful waiting: This strategy also starts by only monitoring the prostate cancer at first. But if the tumor starts growing, only the symptoms are treated, not the tumor itself (this is known as “palliative care). This approach is mainly considered in older men, who may also have other medical problems. The risks and stress of surgery or radiotherapy could outweigh the possible benefits of this treatment.There is no “right” or “wrong” treatment decision for men who have low-risk prostate cancer. The strategy that one man chooses will mainly depend on his personal preferences and values. Some will feel it is more important to avoid side effects like impotence or incontinence as much as possible. Others will want to be very sure that the cancer has been removed, so they are willing to accept the risks associated with treatment.For more advanced stages of prostate cancer, there are several kinds of hormonal treatments and chemotherapies that aim to slow the growth.

FDA approved drugs:

(show all 17)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Degarelix 18 49 degarelix Ferring Pharmaceuticals December of 2008
2
Eligard 18 49 LEUPROLIDE ACETATE Atrix Laboratories January 2002
3
Eulexin 18 FLUTAMIDE Schering-Plough June 1996
4
Iressa 18 49 GEFITINIB AstraZeneca May 2003
5
Jevtana 18 49 CABAZITAXEL sanofi aventis June 2010
6
Lupron Depot 18 49 LEUPROLIDE ACETATE TAP Pharmaceuticals/ Abbott Laboratories July 1997/ January 1996
7
Plenaxis 18 ABARELIX Praecis Pharmaceuticals December 2003
8
Provenge 18 49 sipuleucel-T Dendreon May 2010
9
Taxotere 18 49 DOCETAXEL Rhone Poulenc Rorer May 1996
10
Trelstar Depot/ Trelstar LA 18 TRIPTORELIN PAMOATE Debio Rechereche Pharmaceutique, Target Research Associates/ Debiopharm June 2000/ June 2001
11
Viadur 18 49 LEUPROLIDE ACETATE Alza March 2000
12
Xgeva 18 49 DENOSUMAB Amgen June 2013/ November 2010
13
Xofigo 18 49 RADIUM RA-223 DICHLORIDE Bayer Healthcare Pharmaceuticals May 2013
14
Xtandi 18 49 ENZALUTAMIDE Medivation August 2012
15
Zoladex 18 49 GOSERELIN ACETATE AstraZeneca January 1996
16
Zometa 18 49 ZOLEDRONIC ACID Novartis August 2001/ February 2002
17
Zytiga 18 49 ABIRATERONE ACETATE Centocor Ortho Biotech May 2011

Drugs for Prostate Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 872)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Goserelin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 65807-02-5 47725 5311128
2
Iodine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7553-56-2 807
3
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 657-24-9 14219 4091
4
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53714-56-0 3911 657181
5
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 164656-23-9 152945 6918296
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
8
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-18-4 6010
9
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 58-22-0 6013
10
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 315-37-7 9416
11
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 5949-44-0
12
Docetaxel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114977-28-5 148124
13
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 53-03-2 5865
14
Bicalutamide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 90357-06-5 56069 2375
15
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-61-6, 62-31-7 681
16
Histamine Approved, Investigational Phase 4,Phase 2 75614-87-8, 51-45-6 774
17
Lenograstim Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
18
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 85721-33-1 2764
19
Ropivacaine Approved Phase 4,Phase 3,Not Applicable 84057-95-4 71273 175805
20
Acetaminophen Approved Phase 4,Phase 2,Phase 1,Not Applicable 103-90-2 1983
21
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 169590-42-5 2662
22
Menthol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2216-51-5 16666
23
Lidocaine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 137-58-6 3676
24
Somatostatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 38916-34-6, 51110-01-1 53481605
25
Flutamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 13311-84-7 3397
26
Sulfamethoxazole Approved Phase 4,Phase 2 723-46-6 5329
27
Trimethoprim Approved, Vet_approved Phase 4,Phase 2 738-70-5 5578
28 sodium fluoride Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 7681-49-4
29
Tamsulosin Approved, Investigational Phase 4,Phase 3,Not Applicable 106133-20-4 129211
30
Finasteride Approved Phase 4,Phase 3,Phase 2,Not Applicable 98319-26-7 57363
31
Zoledronic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 118072-93-8 68740
32
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
33
Diphenhydramine Approved, Investigational Phase 4,Phase 2,Phase 1 147-24-0, 58-73-1 3100
34
Granisetron Approved, Investigational Phase 4 109889-09-0 3510
35
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
36
Ondansetron Approved Phase 4 99614-02-5 4595
37
Promethazine Approved, Investigational Phase 4,Phase 2,Phase 1 60-87-7 4927
38
Ranitidine Approved Phase 4,Phase 2 66357-59-3, 66357-35-5 3001055
39
Etidronic acid Approved Phase 4,Phase 3 7414-83-7, 2809-21-4 3305
40
Desflurane Approved Phase 4 57041-67-5 42113
41
Nitric Oxide Approved Phase 4,Phase 2,Not Applicable 10102-43-9 145068 160954
42
Propofol Approved, Investigational, Vet_approved Phase 4,Not Applicable 2078-54-8 4943
43
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
44
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
45
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
46
Sevoflurane Approved, Vet_approved Phase 4,Not Applicable 28523-86-6 5206
47
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2 60142-96-3 3446
48
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2 56-12-2 119
49
Hydromorphone Approved, Illicit Phase 4,Phase 3 466-99-9 5284570
50
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603

Interventional clinical trials:

(show top 50) (show all 4261)
# Name Status NCT ID Phase Drugs
1 FINNPROSTATE Study VII: Intermittent Versus Continuous Androgen Deprivation in Patients With Advanced Prostate Cancer Unknown status NCT00293670 Phase 4 Goserelin (Zoladex)
2 Treatment of Localized Prostate Cancer With High Intensity Focused Ultrasound Using the Sonablate® 500 System in Canada Unknown status NCT00573586 Phase 4
3 Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy Unknown status NCT01379742 Phase 4
4 MR-Lymphography and Lymph Node Staging in Prostate Cancer Unknown status NCT00185029 Phase 4
5 Metformin And Longevity Unknown status NCT02511665 Phase 4 Metformin;Placebo
6 Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer Unknown status NCT00906269 Phase 4 Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
7 Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer Completed NCT00199485 Phase 4 Angelica Sinensis
8 Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer Completed NCT01511874 Phase 4 ELIGARD 22.5mg
9 A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer Completed NCT02116582 Phase 4 Enzalutamide
10 Assessment Of Dutasteride (AVODART) In Extending The Time To Progression Of Low-Risk, Localized Prostate Cancer In Men Completed NCT00363311 Phase 4 Dutasteride;Matching placebo
11 3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer Completed NCT01296672 Phase 4 Finasteride;Placebo
12 Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases Completed NCT00219219 Phase 4 Zoledronic acid
13 Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer Completed NCT00219271 Phase 4 Zoledronic acid
14 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
15 A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade Therapy Completed NCT02405858 Phase 4 Abiraterone Acetate;Prednisolone
16 Evaluate Recovery of Testosterone for Patients Using Eligard Completed NCT01136226 Phase 4 Eligard (TM)
17 Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis Completed NCT00035997 Phase 4 Zometa
18 Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy Completed NCT00237146 Phase 4 Zoledronic acid
19 Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer Completed NCT00391690 Phase 4 Zoledronic acid
20 A Study to Evaluate the Efficacy and Tolerability of Zoledronic Acid in Patients With Metastatic Prostate Cancer Who Can be Treated With a Group of Medications Known as Bisphosphonates Completed NCT00172016 Phase 4 Zoledronic acid
21 Evaluation of Safety of Cabazitaxel (Jevtana) in Patients With Metastatic Hormone Refractory Prostate Cancer Completed NCT02074137 Phase 4 CABAZITAXEL XRP6258;Prednisone;Prednisolone
22 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
23 Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation Completed NCT00805701 Phase 4 avodart;Placebo
24 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
25 Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases Completed NCT00242554 Phase 4 Zoledronic acid
26 Study to Monitor the Effects of Androgen Suppression Treatment on the Heart Completed NCT01230905 Phase 4
27 Casodex/Zoladex Biomarkers in Localised Prostate Cancer Completed NCT00293696 Phase 4 bicalutamide (Casodex), goserelin (Zoladex)
28 Docetaxel in the Treatment of Hormone Refractory Prostate Cancer Completed NCT00280098 Phase 4 docetaxel
29 Combination of Cabazitaxel With Prednisolone With Primary Prophylaxis With PEG-G-CSF in Treatment of Patients With Prostate Cancer Completed NCT02441894 Phase 4 CABAZITAXEL XRP6258;PEG-G-CSF;Prednisolone;Dexchlorpheniramine or Diphenhydramine;Ranitidine;Metoclopramide, Granisetron, or Ondansetron;Dexamethasone
30 Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy Completed NCT00470834 Phase 4 dutasteride;placebo;bicalutamide
31 A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer Completed NCT00220194 Phase 4 leuprolide acetate
32 Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX Completed NCT00590213 Phase 4 Casodex 150mg
33 Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer Completed NCT01649635 Phase 4 CABAZITAXEL (XRP6258);Prednisone;Ciprofloxacin;G-CSF (Granulocyte colony-stimulating factor)
34 Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
35 The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy Completed NCT00063609 Phase 4 zoledronic acid
36 Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration Completed NCT01161563 Phase 4 Triptorelin pamoate;Leuprolide acetate
37 Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer Completed NCT00859027 Phase 4 risedronate;Placebo risedronate oral tablet
38 Effect of Soy on Cognition and Hot Flashes in Men With Prostate Cancer Undergoing Testosterone Suppression Therapy Completed NCT00245518 Phase 4 Isoflavone;Placebos
39 Assessment of Pain and Quality of Life in Breast and Prostate Cancer Patients With Bone Metastases Completed NCT00434317 Phase 4 Zoledronic acid
40 Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer Completed NCT00334139 Phase 4 Zoledronic Acid
41 Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer Completed NCT00953277 Phase 4
42 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4 Triptorelin
43 Global Performance Evaluation of the AMS CONTINUUM™ Device Completed NCT01083199 Phase 4
44 The Effect of Propofol Based Total Intravenous Anesthesia on Oxidative Stress and Nitric Oxide Completed NCT02149628 Phase 4 propofol;Desflurane
45 The Use of Thermal Suits as Preventing Hypothermia During Surgery Completed NCT01571544 Phase 4
46 The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function Completed NCT01547416 Phase 4 epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose;no epidural drug administered
47 Hydroxyethyl Starch and Renal Function After Radical Prostatectomy Completed NCT01486563 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9 mg/ml
48 Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy? Completed NCT00982800 Phase 4 Gabapentin;Placebo Sugar Pill
49 Radical Prostatectomy and Perioperative Fluid Therapy Completed NCT00771966 Phase 4
50 Local Anesthesia for Prostate Biopsy Completed NCT00422708 Phase 4

Search NIH Clinical Center for Prostate Cancer

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Prostate Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Prostate Cancer:
Alescat, autologous lymphocyte-based therapy for the treatment of solid cancers

Cochrane evidence based reviews: prostatic neoplasms

Genetic Tests for Prostate Cancer

Genetic tests related to Prostate Cancer:

# Genetic test Affiliating Genes
1 Malignant Tumor of Prostate 29 AR BRCA2 CD82 CDH1 CHEK2 HIP1 KLF6 MAD1L1 MSR1 MXI1 PTEN ZFHX3
2 Familial Prostate Cancer 29
3 Prostate Neoplasm 29

Anatomical Context for Prostate Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Prostate Cancer:

19
The Prostate

MalaCards organs/tissues related to Prostate Cancer:

41
Prostate, Bone, Lymph Node, Testes, Lung, Endothelial, T Cells

Publications for Prostate Cancer

Articles related to Prostate Cancer:

(show top 50) (show all 18187)
# Title Authors Year
1
Ga-68-PSMA PET/CT in treatment-naA^ve patients with prostate cancer: Which clinical parameters and risk stratification systems best predict PSMA-positive metastases? ( 29978529 )
2018
2
Possible association between androgenic alopecia and risk of prostate cancer and testicular germ cell tumor: a systematic review and meta-analysis. ( 29529997 )
2018
3
Positive Association between Preoperative Total Testosterone Levels and Risk of Positive Surgical Margins by Prostate Cancer: Results in 476 Consecutive Patients Treated Only by Radical Prostatectomy. ( 29975957 )
2018
4
Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. ( 29978216 )
2018
5
Anti-oxidants as chemopreventive agents in prostate cancer: A gap between preclinical and clinical studies. ( 29446748 )
2018
6
PPARI' Elicits Ligand-Independent Repression of Trefoil Factor Family to Limit Prostate Cancer Growth. ( 29187400 )
2018
7
Guided undersampling classification for automated radiation therapy quality assurance of prostate cancer treatment. ( 29377156 )
2018
8
Volumetric-based image guidance is superior to marker-based alignments for stereotactic body radiotherapy of prostate cancer. ( 29450961 )
2018
9
Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy. ( 29293372 )
2018
10
Relevance of poly (ADP-ribose) polymerase inhibitors in prostate cancer. ( 29979319 )
2018
11
Glucose metabolism during the acute prostate cancer treatment trajectory: The influence of age and obesity. ( 27998647 )
2018
12
Systems pharmacology using mass spectrometry identifies critical response nodes in prostate cancer. ( 29977602 )
2018
13
A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models. ( 29981500 )
2018
14
Informational needs during active surveillance for prostate cancer: A qualitative study. ( 28886974 )
2018
15
Heteronormativity and prostate cancer: A discursive paper. ( 28382781 )
2018
16
TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways. ( 29449534 )
2018
17
Efficacy, Predictive Factors, and Prediction Nomograms for <sup>68</sup>Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. ( 29358059 )
2018
18
Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. ( 29254781 )
2018
19
Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. ( 29980832 )
2018
20
Genome-Wide Methylation Patterns in Androgen-Independent Prostate Cancer Cells: A Comprehensive Analysis Combining MeDIP-Bisulfite, RNA, and microRNA Sequencing Data. ( 29324665 )
2018
21
Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. ( 29138344 )
2018
22
The impact on oncologic outcomes after radical prostatectomy for prostate cancer of converting soft tissue margins at the apex and bladder neck from tumor positive to negative. ( 29978558 )
2018
23
Increased risk of a herpes zoster attack in patients receiving androgen deprivation therapy for prostate cancer. ( 28786220 )
2018
24
Gambogic Acid Induces Cell Apoptosis and Inhibits MAPK Pathway in PTEN<sup>-/-</sup>/p53<sup>-/-</sup>Prostate Cancer Cells In Vitro and Ex Vivo. ( 28578487 )
2018
25
Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug-Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients. ( 29150561 )
2018
26
New prostate cancer grade grouping system predicts survival after radical prostatectomy. ( 29447924 )
2018
27
Malignant invasion of the central nervous system: the hidden face of a poorly understood outcome of prostate cancer. ( 29980839 )
2018
28
The Impact of<sup>68</sup>Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study. ( 28646014 )
2018
29
Reversible intrahepatic cholestasis in metastatic prostate cancer: An uncommon paraneoplastic syndrome. ( 29541472 )
2018
30
Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer. ( 29448139 )
2018
31
Correction to: MRI/US fusion-guided biopsy: performing exclusively targeted biopsies for the early detection of prostate cancer. ( 29318440 )
2018
32
Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. ( 29980331 )
2018
33
Utility of F-18 FDG PET/CT for Detection of Bone Marrow Metastases in Prostate Cancer Patients Treated with Radium-223. ( 29333469 )
2018
34
Mediterranean diet after prostate cancer diagnosis and urinary and sexual functioning: The health professionals follow-up study. ( 29194691 )
2018
35
Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. ( 29336978 )
2018
36
Metastatic prostate cancer mimicking a subdural hematoma: A case report and literature review. ( 29980476 )
2018
37
Dioxin Exposure in the Manufacture of Pesticide Production as a Risk Factor for Death from Prostate Cancer: A Meta-analysis. ( 29445624 )
2018
38
Lenalidomide decreased the PSA level for castration-resistant prostate cancer: a case report. ( 29445483 )
2018
39
An improved distance-to-dose correlation for predicting bladder and rectum dose-volumes in knowledge-based VMAT planning for prostate cancer. ( 29131812 )
2018
40
Dual inhibition of BRD4 and PI3K by SF2523 suppresses human prostate cancer cell growth inA vitro and inA vivo. ( 29133261 )
2018
41
The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications. ( 29757368 )
2018
42
Prediction of Prostate Cancer Risk Among Men Undergoing Combined MRI-targeted and Systematic Biopsy Using Novel Pre-biopsy Nomograms That Incorporate MRI Findings. ( 29155186 )
2018
43
The use of polysulfated polysaccharides heparin like compounds, glycosaminoglycans and Vitamin B17 as a possible treatment for prostate cancer. ( 29447928 )
2018
44
Randomized controlled trial of a peer led multimodal intervention for men with prostate cancer to increase exercise participation. ( 28685892 )
2018
45
De novo neurogenic bladder dysfunction after salvage lymph node dissection in patients with nodal recurrence of prostate cancer. ( 29504654 )
2018
46
Manganese Inhibits Viability of Prostate Cancer Cells. ( 29277766 )
2018
47
Three-dimensional reconstruction of prostate cancer architecture with serial immunohistochemical sections: hallmarks of tumour growth, tumour compartmentalisation, and implications for grading and heterogeneity. ( 29323728 )
2018
48
Evaluation of Tumor Viability for Primary and Bone Metastases in Metastatic Castration-Resistant Prostate Cancer Using Whole-Body Magnetic Resonance Imaging. ( 29977641 )
2018
49
Prospective Randomized Controlled Trial Exploring the Effect of TachoSil on Lymphocele Formation After Extended Pelvic Lymph Node Dissection in Prostate Cancer. ( 29775698 )
2018
50
Meta-analysis of CDKN2A methylation to find its role in prostate cancer development and progression, and also to find the effect of CDKN2A expression on disease-free survival (PRISMA). ( 29561434 )
2018